Regulus, GlaxoSmithKline deal

Regulus and GlaxoSmithKline partnered to develop and commercialize therapeutics targeting microRNA-122 for all indications, with HCV as the lead indication. Regulus expects to identify a clinical development candidate next half and submit an IND next year. GSK, which will have exclusive, worldwide rights to the therapeutics, is responsible for funding all trials after proof of concept (POC). Regulus is eligible for more than $150 million in upfront and milestone payments, plus tiered royalties up to double-digits.

In a separate 2008 deal, Regulus and GSK partnered to discover, develop and market microRNA-targeted therapeutics to treat inflammatory diseases (see BioCentury, April 21, 2008). ...